James Wells is an Oncology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
222 E Medical Ln Ste 400
West Columbia, SC 291694848
Telephone
803-794-7511Provider last certified this registry record 11 Nov 2020.
Clinical trials
1 registered study on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20257 payments
- Daiichi Sankyo Inc.Program year20253 payments
- ABBVIE INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.2%PD-1 inhibitor24.9%Pembrolizumab52%Nivolumab41%Atezolizumab7%Part B, office-administered≥58 patientsPlatinum-based Drug9.5%Oxaliplatin96%Carboplatin2%Cisplatin2%Part B, office-administered≥28 patients+ 14 more classes in this area
Blood & clotting
24.1%Iron, parenteral preparations23.1%Ferric carboxymaltose100%Part B, office-administered≥43 patientsErythropoiesis-stimulating Agent0.9%Epoetin alfa100%Part B, office-administered≥15 patients+ 3 more classes in this area
Metabolism & gastrointestinal
18.9%Other antiemetics11%Fosaprepitant100%Part B, office-administered≥75 patientsSubstance P/Neurokinin-1 Receptor Antagonist4.3%Aprepitant100%Part B, office-administered≥38 patients+ 10 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”